Literature DB >> 28258940

Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity.

Halley M Wasserman1, Lindsey N Hornung2, Peggy J Stenger3, Meilan M Rutter3, Brenda L Wong4, Irina Rybalsky4, Jane C Khoury5, Heidi J Kalkwarf6.   

Abstract

Patients with Spinal Muscular Atrophy (SMA) are at risk for poor bone health. The prevalence of fractures, low areal bone mineral density (aBMD; Z-score ≤-2.0) of the lateral distal femur and of osteoporosis by SMA subtype is not known. We aimed to describe the natural history of bone health in patients with SMA prior to bisphosphonate treatment. We reviewed data from 85 eligible patients with SMA ages 12 months to 18 years, seen at a single institution between January 2005 and July 2016. Fracture history was reported at annual clinic visits. aBMD was obtained from dual energy x-ray absorptiometry scans of the lumbar spine, total body, and lateral distal femur. 85% of patients had aBMD Z-scores ≤-2.0 SD and were progressively lower with worsening SMA severity. Longitudinal aBMD Z-scores of the lateral distal femur decreased with age. Fractures occurred in 38% (32/85) of patients with the femur being the most common location (25 of 57 fractures). Thirteen percent of patients fulfilled criteria for osteoporosis. Low aBMD and femur fractures are highly prevalent in all SMA subtypes from a young age; however, few patients met the criteria for osteoporosis. Poor bone health may be an under-recognized comorbidity of SMA.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Children; Dual energy x-ray absorptiometry; Osteoporosis

Mesh:

Year:  2017        PMID: 28258940      PMCID: PMC6448139          DOI: 10.1016/j.nmd.2017.01.019

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  12 in total

Review 1.  The Utility of DXA Assessment at the Forearm, Proximal Femur, and Lateral Distal Femur, and Vertebral Fracture Assessment in the Pediatric Population: 2019 ISCD Official Position.

Authors:  David R Weber; Alison Boyce; Catherine Gordon; Wolfgang Högler; Heidi H Kecskemethy; Madhusmita Misra; Diana Swolin-Eide; Peter Tebben; Leanne M Ward; Halley Wasserman; Christopher Shuhart; Babette S Zemel
Journal:  J Clin Densitom       Date:  2019-07-10       Impact factor: 2.617

2.  Intravenous bisphosphonate therapy in children with spinal muscular atrophy.

Authors:  N Nasomyont; L N Hornung; H Wasserman
Journal:  Osteoporos Int       Date:  2019-12-02       Impact factor: 4.507

3.  Phosphoethanolamine Elevation in Plasma of Spinal Muscular Atrophy Type 1 Patients.

Authors:  Mawaddah Ar Rochmah; Yogik Onky Silvana Wijaya; Nur Imma Fatimah Harahap; Chisato Tode; Atsuko Takeuchi; Kazuki Ohuchi; Masamitsu Shimazawa; Hideaki Hara; Michinori Funato; Toshio Saito; Kayoko Saito; Poh San Lai; Hiroyuki Awano; Masakazu Shinohara; Hisahide Nishio; Emma Tabe Eko Niba
Journal:  Kobe J Med Sci       Date:  2020-04-01

Review 4.  Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

Authors:  Natalia N Singh; Shaine Hoffman; Prabhakara P Reddi; Ravindra N Singh
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-01-05       Impact factor: 5.187

5.  Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015.

Authors:  Kevin B Dagbay; Erin Treece; Frederick C Streich; Justin W Jackson; Ryan R Faucette; Anastasia Nikiforov; Susan C Lin; Chris J Boston; Samantha B Nicholls; Allan D Capili; Gregory J Carven
Journal:  J Biol Chem       Date:  2020-02-19       Impact factor: 5.157

Review 6.  Metabolic and Nutritional Issues Associated with Spinal Muscular Atrophy.

Authors:  Yang-Jean Li; Tai-Heng Chen; Yan-Zhang Wu; Yung-Hao Tseng
Journal:  Nutrients       Date:  2020-12-16       Impact factor: 5.717

7.  Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice.

Authors:  Eike A Strathmann; Miriam Peters; Seyyedmohsen Hosseinibarkooie; Frank W Rigo; C Frank Bennett; Phillip G Zaworski; Karen S Chen; Michael Nothnagel; Brunhilde Wirth
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

8.  Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy.

Authors:  Kimberly K Long; Karen M O'Shea; Ramzi J Khairallah; Kelly Howell; Sergey Paushkin; Karen S Chen; Shaun M Cote; Micah T Webster; Joseph P Stains; Erin Treece; Alan Buckler; Adriana Donovan
Journal:  Hum Mol Genet       Date:  2019-04-01       Impact factor: 6.150

Review 9.  Metabolic Dysfunction in Spinal Muscular Atrophy.

Authors:  Marc-Olivier Deguise; Lucia Chehade; Rashmi Kothary
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

10.  Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease.

Authors:  Brian T Welsh; Shaun M Cote; Deborah Meshulam; Justin Jackson; Ajai Pal; Janice Lansita; Ashish Kalra
Journal:  Int J Toxicol       Date:  2021 Jul-Aug       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.